ATNM could change the way we treat cancer
Good day everyone,
Today we are revisiting a stock we’ve covered in the past, Actinium Pharmaceuticals, Inc. (NYSE: ATNM), a clinical stage biopharma company.
Current price $.27 per share
News out today: Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma – More about this news coming soon – https://finance.yahoo.com/news/actinium-pharmaceuticals-announces-iomab-act-120300184.html
We are revisiting these shares because the company has advanced into late stage Phase III clinical trials and the shares are available at a value price.
Analysts are projecting potential gains over 1000%
Actinium is developing Actinium-225 Radio-Conjugates (ARCs) using its Actinium Warhead Enabling (AWE) Platform Technology.
For those unfamiliar with the ATNM platform, please read the brief paragraph below. The platform is the cornerstone of the company’s operations and development.
The AWE technology precisely targets radiation to tumors. AWE conjugates exploit the use of highly selective targeted biological agents such as monoclonal antibodies that can seek out and bind cancer antigens found on the tumor cell surface. Once there, the AWE conjugate delivers a potent tumor-destroying dose of the radiation from the actinium warhead. The power of this technology lies in its alpha emitting payload actinium-225. It emits a powerful dose of high energy but only over a very short distance – about the distance of a few cells or less than the thickness of a piece of paper. This focuses the radiation on the cancer cells and limits exposure to normal tissues. The energy delivered is so strong that one or two targeted actinium warheads may be sufficient to kill a tumor cell.
In addition to the AWE platform, which is also being used in collaborations with other companies, ATNM is developing its own conjugates to use with the platform:
Its lead product candidate, Iomab-B, is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The SIERRA trial is over fifty percent enrolled and promising single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings. Last month ATNM announced it’s advancing the development of low dose Iodine-131 apamistamab, a CD45 targeting antibody radiation-conjugate (ARC), as an alternative to today’s standard practice of chemotherapy-based lymphodepletion regimens like fludarabine/cyclophosphamide (Flu/Cy), which have been implicated in CAR-T toxicities including cytokine release syndrome (CRS) and neurotoxicity.
The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over. In December, the company announced results from a Phase 1 trial studying Actimab-A in combination with the salvage chemotherapy regimen CLAG-M. Patients receiving Actimab-A at a dose of 0.50 uCi/kg in the second dose cohort in addition to CLAG-M had an 86% overall response rate.
Actimab-M, a drug candidate, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial.
Reasons ATNM may be a near term opportunity:
Three Wall Street analysts have issued ratings and price targets for Actinium Pharmaceuticals in the last 12 months. Their average twelve-month price target is $3.25, suggesting that the stock has a possible upside of 1,184.58%. The high price target for ATNM is $5.00 and the low-price target for ATNM is $1.50. There are currently 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”
12/11/2019 Maxim Group Reiterated Rating Buy $1.50
8/8/2019 William Blair Initiated Coverage Outperform
2/26/2019 Oppenheimer Set Price Target Buy $5.00
The 52-week range for ATNM shares is $.19 to $.71, including a price of $.41 at the end of October. An advance in the share price, to the recent high just 10 weeks ago, would be a 62% increase.
ATNM has no long-term debt on its most recent balance sheet.
ATNM shares are 22% owned by institutions. Hedge funds make up the majority of that institutional ownership. Hedge funds have a fairly good record of outperforming the markets.
Note in the chart below, that ATNM shares have crossed their 50 DMA of $.23 per shares and are closing in on their 200 DMA of $.27 per share. We believe that crossing these thresholds could result in a significantly improved share price in the near term.
Updated report coming soon…
The Traders News Group
TradersNewsSource.com collects your contact information to keep you informed about updates to our web site, newsletters and social channels. All information is kept secure, with only authorized employees having access.
TradersNewsSource.com does from time to time, issue releases to subscribers as “Feature Reports” that may be related to our content partners or advertising sponsors.
We do not sell your contact information to other organizations for commercial purposes. We will not release your email address to anyone, unless you specifically give us permission to do so. Should you decide in the future to unsubscribe from TradersNewsSource.com at any time, simply follow the instructions located at the bottom of each newsletter edition. Your email address will be kept strictly confidential, and will never be shared with anyone for any purpose of any kind.
Regarding Google ads:
ALL STOCKS INVOLVE RISKS AND THE POSSIBILITY OF LOSING ALL OF YOUR INVESTMENT. PLEASE CONSIDER ALL RISKS BEFORE INVESTING.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. TNS LLC’s parent company has been compensated twelve thousand dollars cash via bank wire by venado media llc for this weeks coverage of atnm. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.